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Background: Few studies have addressed the biological features of medullary breast carcinoma (MBC) in the
context of clinical outcomes. We sought to compare the baseline demographics, standard pathologic factors and
long-term clinical outcomes between MBC and infiltrating ductal carcinoma-not otherwise specified (IDC-NOS)
using a large database.
Methods: A total of 2,202 cases with pure IDC-NOS and 188 cases with typical MBC meeting the inclusion criteria
were identified. The clinical and biological features, the overall survival (OS) and recurrence/metastasis-free survival
(RFS) were compared for both groups.
Results: There were a higher proportion of patients diagnosed prior to 40 years of age in the MBC group
compared to the IDC-NOS group. MBC cases demonstrated less aggressive tumor features such as lower tumor
stage, smaller tumor size and a lower proportion of nodal involvement than IDC-NOS; however,
immunohistochemical staining revealed that MBC displayed the triple-negative phenotype more often than
IDC-NOS cases (40.4% versus 26.2%; P <0.001). Although the clinical behavior of MBC was not commensurate with
its pathologic features, women diagnosed with MBC had a lower frequency of recurrence/metastasis (P = 0.032)
and death (P = 0.042) than those with IDC-NOS, and the 10-year OS and RFS were significantly higher for MBC
(91% and 74%) compared to IDC-NOS (81% and 64%). Moreover, multivariate analysis revealed that TNM stage was
a statistically significant factor for survival.
Conclusions: MBC in Chinese women demonstrated less aggressive behavior and better prognosis than IDC-NOS.
This favorable outcome was maintained after 10 years.
Keywords: Medullary breast carcinoma, Tumor characteristics, Clinical outcomesBackground
Medullary breast carcinoma (MBC) accounts for less than
5% of all invasive breast cancers, and usually presents dis-
tinct clinicopathologic characteristics from infiltrating
ductal carcinoma-not otherwise specified (IDC-NOS) [1].
Histologically, the tumor is characterized by the medullary* Correspondence: didy@medmail.com.cn
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reproduction in any medium, provided the orgrowth of large cells with a high histological grade (par-
ticularly high mitotic count), circumscribed edges, central
fibrosis and necrosis, and is often accompanied by lympho-
cytic infiltration [2].
Medullary carcinoma has long garnered interest due to
its morphological and immunophenotypical association
with two of the most controversial entities in breast can-
cer: BRCA1-linked tumors, which often exhibit a much
higher rate of MBC and are very frequently estrogen
receptor (ER)-negative, and basal-like cancers, which
express at least one basal marker [3]. Genetic alterations
in the most common tumor suppressor gene, p53, are. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the percentage of human epidermal growth factor recep-
tor 2 (HER2/neu) expression in MBC was reported to
range from 10% to 33% [5]. The detection of alterations
in these genes would allow us to understand the nature
of MBC more clearly and to create new gene therapy
strategies in the future.
Despite its aggressive histological features (such as the
lack of hormonal receptors and grade of 3), medullary
carcinoma has a better prognosis than non-medullary
carcinoma. Several studies have reported favorable out-
comes for MBC based on relapse-free survival or overall
survival (OS) [6-8], and MBC has superior survival com-
pared to IDC-NOS, with 10-year survival rates ranging
up to 84% [9]. Furthermore, a comparison of 20-year
survival outcome using the data in the published series
by Richardson et al. found that the 20-year survival rate
was 14% better than for non-medullary carcinoma [10].
Although some studies have reported tumors in women
with MBC, there is no consensus regarding the clinico-
pathologic characteristics and long-term outcomes of
MBC, or whether it is different from IDC-NOS in terms
of prognostic factors. We therefore undertook an exten-
sive comparison of MBC and IDC-NOS using a large
database to provide a more complete and reliable assess-
ment of the biological phenotypes and clinical behaviors.
The present population-based study elucidated the prog-
nosis of MBC and IDC-NOS in terms of recurrence/me-
tastasis-free survival (RFS) and OS in Chinese women.
Methods
Patients and follow-up
We retrospectively reviewed the consecutive data of 188
patients with MBC, ascertained by histopathological exa-
mination and treated at the Department of Breast Sur-
gery, Cancer Hospital/Cancer Institute, Fudan University
(Shanghai, China), during the period of 1 January 1999 to
1 October 2010. According to the number of patients with
MBC who were enrolled every year during the study
period, a similar proportion of patients with infiltrating
ductal carcinoma (IDC) were randomly selected in the
corresponding year, and a total of 2,202 patients with IDC-
NOS were recruited and enrolled as controls. Tumors
were classified histologically as MBC or IDC-NOS only
according to the WHO classification criteria. The patients
were all female, without distant metastasis at first diagno-
sis, and with typical MBC [11] and pure IDC according to
the inclusion criteria. MBC was not further subtyped in
these databases, and patients with mixed MBC and IDC
were excluded. Histological grade and lymphovascular in-
vasion were not analyzed in the present study because in
many cases this information was not available.
All patients were required to undertake a complete phy-
sical examination, bilateral mammography, chest radio-scopy, ECG, ultrasonography of breasts, axillary fossa, cer-
vical parts, abdomen and pelvis, and routine blood and
biochemical tests, before surgery and accompanying adju-
vant therapy, according to the standards that were used
during surgery. All the patients who had relapse risks re-
ceived adjuvant chemotherapy of different regimens for 4
to 6 cycles followed by local radiotherapy (if required)
and/or hormonotherapy (if required), according to the
standard therapy at the time of surgery. All the partici-
pants gave informed consent. This project was approved
by the Scientific and Ethical Committee of the Cancer
Hospital of Fudan University.
Follow-up data were collected annually from medical
records for breast cancer recurrence, new primary can-
cers and death. Personal contact with patients, including
routine correspondence or telephone visits, was used to
follow the patients. The follow-up examinations were
carried out at the Cancer Hospital of Fudan University
every 3 months during the first 2 years, every 6 months
during the next 2 years and once a year thereafter.
Methods for biological characteristics
The immunohistochemical status of each postoperative
paraffin-embedded tumor sample was defined through
immunohistochemical staining, including antibodies to
ER, progesterone receptor (PR) and HER2/neu (All pri-
mary monoclonal antibodies were provided by Dako).
All the primary monoclonal antibodies were purchased
from Dako (Hamburg, Germany). The detailed staining
procedures were performed strictly according to the
manufacturer’s instructions. Negative controls were
obtained by incubating parallel slides without primary
antibodies. Sections known to be stained positively in
each run served as positive controls. The percentage and
intensity score of stained tumor cells (ER, PR, HER2/
neu, p53, cathepsin-D and proliferating cell nuclear anti-
gen (PCNA)) were determined by at least two indepen-
dent pathologists. The percentage was interpreted as
follows: 0, no staining observed; 1, ≤25% of cells with
positive staining; 2, 25% to 50%; 3, 50% to 75%; and 4,
75%. In terms of the intensity score, a score of 0 referred
to a negative result, 1 to a weakly positive result, 2 to a
moderately positive result and 3 to a strongly positive
result. The two scores were combined and produced a
final score. For all these markers except HER2/neu stai-
ning, a score of 0 was defined as negative and 1 to 12 as
positive, while strong membranous staining scores of 9
to 12 (DAKO score 3+) were defined as positive.
Statistical analysis
The association of clinicopathologic factors was evalua-
ted using Pearson’s chi-squared test or Fisher’s exact
test. The primary clinical outcomes for this study were
RFS and OS. OS was defined as the time from the first
Table 1 Baseline characteristics and treatment patterns of
all patients
Characteristics MBC IDC-NOS P value
n = 188 n = 2,202
n % n %
Age (years)
≤40 31 16.5. 290 13.2 0.200
>40 157 83.5 1,912 86.8
Tumor size
T ≤2 82 43.4 623 28.3 <0.001
2< T ≤5 102 54.0 1,277 58.0
T >5 5 2.6 170 7.7
Unknown 0 0 132 6.0
Nodal status
0 132 70.2 1,130 51.3 <0.001
1 to 3 45 23.9 559 25.4
4 to 10 8 4.3 347 15.8
>10 3 1.6 110 5.0
Unknown 0 0 56 2.5
TNM stage
I 61 32.4 433 19.7 <0.001
II 117 62.2 1,537 69.8
IIA 102 54.3 1,253 56.9
IIB 15 8.0 284 12.9
III 10 5.3 215 9.8
Unknown 0 0 17 0.8
ER status
Negative 111 59.0 1,167 53.0 0.005
Positive 62 33.0 1,028 46.7
Unknown 15 8.0 7 0.3
PR status
Negative 82 38.0 1,100 50.0 0.005
Positive 119 55.1 1,053 47.8
Unknown 15 6.9 49 2.2
HR status
Negative 94 50.0 785 35.6 <0.001
Positive 79 42.0 1,395 63.4
Unknown 15 8.0 22 1.0
HER2/neu status
Negative 142 68.3 1,512 68.7 0.003
Positive 27 13.0 546 24.8
Unknown 39 18.8 144 6.5
Triple-negative
Yes 76 40.4 550 26.2 <0.001
No 107 56.9 1,610 71.8
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cause, and RFS was defined as the time from the same
starting point to local recurrence or metastasis. Survival
time was calculated from the date of surgery to these
endpoints, censoring at the date of last contact and non-
breast primaries. The 10-year survival rate was calcu-
lated using the Life Tables method. Survival curves were
obtained using the Kaplan-Meier method, and the log
rank test was used to determine the statistical signifi-
cance in comparative survival for a variety of patient and
tumor characteristics. All of the statistically significant
variables observed in univariate analysis were investi-
gated by means of multivariate analysis using the Cox
proportional hazards model. All P values <0.05 were
considered statistically significant. All P values are two-
sided. The SPSS 15.0 software package (SPSS Inc, IBM,
Armonk, NY, USA) was used for statistical analysis.
Results
Patient characteristics
The MBC group comprised 188 patients between the
ages of 26 years and 82 years; the mean age was 52.1
years. The IDC-NOS group comprised 2,202 patients be-
tween the ages of 23 years to 90 years; the mean age was
51.8 years. The clinical characteristics of patients in the
medullary cohort compared with those of the IDC-NOS
control group are presented in Table 1.
MBCs were much more likely to be smaller on average
(43.4% smaller than 2 cm) than IDC-NOS (28.3% sma-
ller than 2 cm; P <0.001) at diagnosis. The frequency of
node-negative disease was higher for the MBC cases
compared to the IDC-NOS cases (70.2% versus 51.3%;
P <0.001), and the MBC cases were more likely to be di-
agnosed with TNM stage I disease (32.4% versus 19.7%;
P <0.001).
The expression of ER was lower in MBC than IDC-
NOS: 33.0% and 46.7%, respectively (P = 0.005). In con-
trast, PR had a relatively higher positive rate in MBC
cases (P = 0.005). Regarding HR (ER or PR) status, the
MBC group also had a relatively higher HR-negative rate
(P <0.001). Of the 169 patients whose HER2/neu status
was known, only 27 patients (15.9%) showed HER2/neu
over-expression, and there was significant difference in
the frequency of triple-negative cases between the MBC
group and IDC-NOS group (40.4% for patients with MBC
versus 26.2% for patients with IDC-NOS; P <0.001). In
addition, there were significant differences between the
two groups in terms of the amplification status of p53,
cathepsin-D and PCNA (p53: P = 0.018; cathepsin-D:
P = 0.001; PCNA: P <0.001).
The surgical management of the breast in all patients
is illustrated in Table 1. At initial assessment, all patients
were offered mastectomy or breast-conserving surgery
Table 1 Baseline characteristics and treatment patterns of
all patients (Continued)
Unknown 5 2.7 42 2.0
Surgery
Mastectomy 181 96.3 2,122 96.4 0.949
BCS 7 3.7 80 3.6
Chemotherapy
Undo 28 14.9 230 10.4 <0.001
Methotrexate included 73 38.8 857 38.9
Anthracyclin included 74 39.4 980 44.5
Taxane included 12 6.4 30 1.4
Others 1 0.5 10 0.5
Unknown 0 0 95 4.3
Radiotherapy
Undo 168 89.4 1,718 78.0 0.002
Do 18 9.6 402 18.3
Unknown 2 1.1 82 3.7
Hormonotherapy
Undo 125 66.5 1,216 55.2 0.002
Do 60 31.9 961 43.6
Unknown 3 1.6 25 1.1
p53
Negative 52 27.7 214 29.7 0.018
Positive 110 58.5 700 31.8
Unknown 26 13.8 848 38.5
Cathepsin-D
Negative 59 31.4 366 16.6 0.001
Positive 94 50.0 1,022 46.4
Unknown 35 18.6 814 37.0
PCNA
Negative 67 36.4 1,270 57.7 <0.001
Positive 87 47.3 484 22.0
Unknown 30 16.3 448 20.3
BCS, breasting-conserving surgery; ER, estrogen receptor; HER2/neu, human
epidermal growth factor receptor 2; HR, hormone receptor; IDC-NOS,
infiltrating ductal carcinoma-not otherwise specified; MBC, medullary breast
carcinoma; PCNA, proliferating cell nuclear antigen; PR, progesterone receptor.
Cao et al. World Journal of Surgical Oncology 2013, 11:91 Page 4 of 9
http://www.wjso.com/content/11/1/91(BCS) in accordance with clinical guidelines. MBC cases
were not different from IDC-NOS cases with regard to
the surgical method. A lower proportion of MBC cases
received adjuvant endocrine therapy (P = 0.002) and no
difference in the frequency of adjuvant chemotherapy
was observed between the groups (P = 0.098). With
regard to other treatment methods, less radiotherapy
was applied to MBC cases (9.6% in MBC patients
versus 18.3% in IDC-NOS patients; P = 0.002), pro-
bably because of the higher fraction of early-TNM
stage patients.Univariate survival analysis
The median follow-up was 44.4 months (range, 5 to 139
months), 64.9 months for the MBC group versus 42.9
months for the IDC-NOS group. Contact with 63 patients
was lost during the follow-up period.
In our cohort, women diagnosed with MBC had a
lower frequency of experiencing recurrence/metastasis
(P = 0.032) and death (P = 0.042) compared to those
with IDC-NOS. MBC was associated with improved
10-year OS and RFS rates (91% and 74%) compared to
IDC-NOS (81% and 64%) (Figure 1A,B) due to its more
favorable biological characteristics. However, after ad-
justment for the common prognostic factors, tumor size
and nodal status, we did not observe a survival benefit
of the MBC histological type.
We further compared 5-year survival rates (RFS and OS)
for T1 triple-negative/node-negative MBC or IDC-NOS
cases receiving chemotherapy versus those not receiving
chemotherapy, and these same comparisons were also
performed in T2 cases (data not shown). The results dem-
onstrated that patients with triple-negative/node-negative
MBC or IDC-NOS with a larger tumor size can gain much
benefit from chemotherapy.
Univariate analysis for RFS according to clinicopatho-
logic characteristics in MBC revealed that TNM stage
was a statistically significant factor for survival (Table 2).
The prognostic value of p53 and PCNA amplification
status was also evaluated, but neither proved to be a
major predictor of worse RFS or OS (RFS: P = 0.328 for
p53 and P = 0.576 for PCNA; OS: P = 0.125 for p53 and
P = 0.425 for PCNA). Furthermore, we found that the
adjuvant treatment methods also had an effect on RFS,
but these findings had not been further validated in the
long-term follow-up and multivariate analysis.
In stage-matched analysis for OS and RFS, MBC
showed a trend toward better survival compared to
IDC-NOS, especially in the TNM stage II cohort, but
this trend was not statistically significant (Figure 2A,B).
Moreover, medullary phenotype was also one of the major
predictors of better survival in the patients who exhibited
larger tumor size (≥2 cm; P = 0.050) (Figure 2D). In our
cohort, MBC patients who received chemotherapy and
did not receive endocrine therapy had a lower rate of
recurrence/metastasis or death compared to their coun-
terparts (Figure 3).
Multivariate survival analysis
Multivariate analysis by Cox regression revealed TNM
stage to be the most significant prognostic factor
(Table 2). Adjuvant radiotherapy was initially associated
with a significant RFS advantage, which was validated
in the following multivariate analysis. Specifically, it did
not significantly improve the RFS for patients younger
than 50 years, with lesions greater than 2 cm in size that
Figure 1 Overall survival (A) and recurrence/metastasis-free survival (B) according to histological type in the general population.
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positive.
Discussion
MBC is a type of invasive breast carcinoma that usually
has unique characteristics in terms of demographics and
clinicopathologic disease. Patients with MBC have con-
tinued to garner interest as a distinct disease entity. In
this study, we examined the associations and prognostic
relevance of medullary histological features in a series of
188 invasive carcinomas compared with IDC-NOS of
the breast.
Some interesting findings were observed in our cohort
of patients with medullary histology. In addition to a de-
tectable difference in mean age at diagnosis between theTable 2 Prognostic significance of clinicopathologic factors an
survival in entire cohort and MBC subset
Covariates Univariate analysis
MBC Entire cohort
Χ2 P Χ2 P
Age ≤50 years <0.001 0.998 0.47 0.490
Tumor size ≥2 cm 0.62 0.432 25.35 <0.001
Node-positive 2.34 0.127 99.36 <0.001
Higher TNM stage 4.53 0.031 95.60 <0.001
ER-positive 0.14 0.706 0.57 0.184
PR-positive 0.04 0.847 0.38 0.103
HER2/neu-positive 1.70 0.193 8.29 0.004
Chemotherapy 1.02 0.314 0.89 0.345
Radiotherapy 7.75 0.005 96.42 <0.001
Hormonotherapy 0.13 0.722 18.70 <0.001
CI, confidence interval; ER, estrogen receptor; HER2/neu, human epidermal growth
RR, relative risk.study cohort and the control group, a higher fraction of
MBCs occurred among the subgroup of young patients,
aged 40 years or younger. A higher fraction of MBC
cases has previously been linked to poor prognosis
[12-14]. Despite its relatively earlier age of onset, these
cases of MBC in our cohort showed less aggressive
tumor features such as lower tumor stage, smaller tumor
size and a lower proportion of nodal involvement than
IDC-NOS, which was not consistent with reports that
cite a significant association of medullary tumors with
adverse prognostic features [15-17]. To our knowledge,
few previous studies have described this finding.
Since only a few scattered studies have addressed the
biological features of MBC, one of the main objectives
of the present study was to more comprehensivelyd influence on long-term recurrence/metastasis-free
Multivariate analysis cox regression of survival
MBC Entire cohort
RR (95% CI) P RR (95% CI) P
1.32 (0.38 to 4.56) 0.666 1.39 (0.91 to 2.12) 0.129
0.42 (0.08 to 2.31) 0.320 2.71 (1.39 to 5.28) 0.003
0.74 (0.16 to 3.53) 0.710 2.40 (1.42 to 4.07) 0.001
7.84 (0.76 to 80.54) 0.083 2.19 (1.33 to 3.62) 0.002
1.15 (0.34 to 3.98) 0.817 0.92 (0.58 to 1.44) 0.697
1.06 (0.28 to 3.92) 0.936 0.80 (0.52 to 1.24) 0.321
1.31 (0.37 to 4.69) 0.677 1.31 (0.86 to 2.00) 0.204
0.37 (0.07 to 2.01) 0.251 0.60 (0.30 to 1.20) 0.151
0.13 (0.03 to 0.71) 0.015 1.81 (1.22 to 2.92) 0.015
0.50 (0.13 to 1.93) 0.317 0.69 (0.43 to 1.01) 0.122
factor receptor 2; MBC, medullary breast carcinoma; PR, progesterone receptor;
Figure 2 Overall survival in TNM stage II (A) and recurrence/metastasis-free survival in stage II (B) according to histological type in the
general population; overall survival (C) and recurrence/metastasis-free survival (D) according to histological type in larger tumor size
(≥2 cm) group.
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finitively confirms and extends the findings of some
previous studies [5-9] which indicated that MBC is sig-
nificantly more likely to be steroid receptor-negative
than IDC-NOS. Our results also demonstrate that MBC
is more likely to exhibit a lack of HER2/neu amplifi-
cation, which shows that medullary carcinomas often
display a triple-negative phenotype and might have
basal-like biological features. Indeed, we found the ex-
pression of basal-associated markers such as basal
cytokeratins (CK5/6, CK17 and CK14) and epidermal
growth factor receptor (EGFR) in more MBC than IDC-
NOS cases (data not shown). Additionally, few reports
have evaluated the common tumor suppressor gene p53
or other prognostic markers such as cathepsin-D and
PCNA, which reflect tumor cell invasion and growth in
MBC, respectively. In the present analysis, positivity for
p53 was found almost twice as often in MBC comparedwith IDC-NOS, and it was similar to the results in some
published series reporting that the frequency of p53 mu-
tations ranged from 50% to 100% [4,5]. In comparison to
the alterations in cathepsin-D and PCNA, which are not
highly correlated to IDC-NOS, almost 50% of tumors
classified as MBCs in our study were characterized by
the positive expression of these two genes. Based on
these findings, MBC in Chinese women seem to be bio-
logically different from IDC-NOS. As a heterogeneous
group of tumors, this basal-like class of breast cancer
encompasses both poor and good prognostic factors.
Although the clinical behavior of MBC is not com-
mensurate to its pathologic features, it is usually thought
to have a more favorable prognosis than IDC-NOS. A
population-based analysis from the Surveillance, Epidemi-
ology and End Results (SEER) database of the National
Cancer Institute (Bethesda, MD, USA) demonstrated that
the 10-year OS rate of MBC was 78%. MBC has superior
Figure 3 Overall survival (A) and recurrence/metastasis-free survival (B) according to histological type in chemotherapy group; overall
survival (C) and recurrence/metastasis-free survival (D) according to histological type in non-hormonotherapy group.
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rates of up to 84% in other studies [8]. The prognosis of
MBC and the 5-year RFS in our database were also very
favorable. This favorable outcome was maintained after 10
years. However, after adjustment for tumor size and nodal
status, we did not observe a significant difference between
the MBC and IDC-NOS groups, which suggested that the
survival advantage of MBC was mainly due to its relatively
earlier TNM stage. TNM stage has been validated as the
most significant independent prognostic factor in multi-
variate analysis. Some previous studies have reported that
the observed favorable survival was extended up to 15
years during the long-term follow-up period. The relapse-
free survival rate was reported to be up to 94.9% in the
MBC group, which was significantly better than that of
the IDC-NOS group (77.5%; P = 0.028) [18]. Our study
also clearly showed that 10-year RFS and OS were signifi-
cantly higher for MBC compared to IDC-NOS, but fur-
ther analysis of more patients with longer follow-up iswarranted to verify the exact favorable effect of MBC in
Chinese women. Furthermore, the univariate beneficial
prognostic effects of the MBC phenotype appear to be re-
stricted to those cases with a larger tumor size and the
majority of patients who received adjuvant chemotherapy
or did not receive hormonotherapy. We therefore inferred
that MBC might be associated with less aggressive bio-
logical behavior than IDC-NOS in some definite sub-
groups and that MBC achieved better chemosensitivity
but lower responsiveness to hormonotherapy than IDC-
NOS, owing to the corresponding immunohistochemical
profiles.
Previous studies have shown nodal status to be the
strongest predictor of disease-specific survival or OS [9].
Steve R et al. demonstrated a poorer 10-year survival in
MBC patients with nodal involvement (67.5%) compared
to those without nodal involvement (81.9%) [8]. Further-
more, in a large study of the effect of nodal involvement
on MBC, patients were categorized as those with and
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for the node-negative patients ranged up to 68.7% to
80.2% [6,19,20]. In the current study, we identified a
trend of poorer RFS and OS in MBC patients with nodal
involvement, but this did not reach statistical signifi-
cance and multivariate analysis did not demonstrate an
effect (P = 0.710). This was probably due to the relatively
small sample size and short duration of follow-up. An-
other limitation was that the pathologic information for
lymphovascular invasion and histological grade were ex-
cluded from the current analysis; these variables could
have had an impaired effect on survival.
\We found that MBCs were treated with BCS as often
as IDC-NOS, and we did not identify any recurrence/
metastasis or death event at an average follow-up period
of 49.6 months. There was recent evidence that the local
control rates among patients with medullary and IDC-
NOS are comparable [18,21]. Although MBCs are more
frequently HR-negative and grade 3, characteristics that
are associated with poor prognosis, they are simultan-
eously of early stage, are HER2/neu-negative and are ap-
propriate candidates for BCS.
Conclusions
MBC in Chinese women showed less aggressive behavior
and better prognosis than IDC-NOS. This relatively large
retrospective comparative analysis confirmed that the ma-
jority of MBC cases typically present in earlier TNM
stages and often display a triple-negative phenotype. TNM
stage appeared to be the most significant predictor of
worse prognosis. With regards to the choice of surgical
procedure, breast-conserving therapy should be preferred
over mastectomy in the treatment of early-stage MBC.
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